PROM1 and cancer: Elevated CD133 expression was observed in several cancers in the TCGA dataset, including colon adenocarcinoma (COAD), cholangiocarcinoma (CHOL), pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), and stomach adenocarcinoma (STAD) (Fig. 1A).